Michael Streit

Dr. Streit brings over 20 years of oncology and clinical development expertise to Scorpion Therapeutics. Prior to joining the company, he served as Vice President, Senior Global Project Head at Sanofi, where he was responsible for leading the development of Sanofi’s precisely PEGylated, not-alpha interleukin-2 candidate. Before that, he served in various roles at GSK where he led the development of multiple oncology medicines, and at Janssen where he worked as the early development lead for the company’s prostate cancer and hematology portfolios.

Dr. Streit received his M.D. from the Free University of Berlin and his M.B.A. in International Business from Golden Gate University, San Francisco. He completed a post-doctoral fellowship in at the Cutaneous Biology Research Center at Massachusetts General Hospital.